Invizyne Awarded $2 Million Grant to Develop Sustainable Aviation Fuel with Cell-Free Biomanufacturing

Invizyne Technologies, Inc. (NASDAQ: IZTC), a leader in cell-free biomanufacturing, announced a $2 million grant to advance the production of sustainable aviation fuel (SAF) using its innovative enzyme-based technology.

The project, a cost-share grant awarded by the U.S. Department of Defense’s BioMADE initiative in collaboration with the University of Georgia, highlights the growing importance of biofuels in achieving environmental sustainability. BioMADE seeks to accelerate the commercialization of American-made biomanufactured products and views Invizyne’s project as a key contributor to this goal.

“This initiative represents a significant step forward for biofuel production,” said Dr. Douglas Friedman, CEO of BioMADE. “By supporting Invizyne’s cell-free approach, we can potentially create a more efficient and sustainable way to meet the growing demand for clean aviation fuels.”

Invizyne’s cell-free technology bypasses the need for living cells, offering a more streamlined and efficient approach to biomanufacturing compared to traditional methods. This grant builds upon Invizyne’s previous $5.85 million grant from the U.S. Department of Energy for the development of cell-free isobutanol production. Isobutanol is a key precursor to SAF, presenting a potential solution for the $27.4 billion global SAF market, projected to grow rapidly in the coming years according to Acumen Research and Consulting.

The BioMADE grant will allow Invizyne to develop a robust enzyme production and processing pipeline for its cell-free isobutanol technology. This includes piloting the process in 100-liter facilities, a crucial step towards large-scale production.

“We believe this project has the potential to revolutionize the biofuel industry,” said Paul Opgenorth, PhD, Co-Founder & VP of Development at Invizyne. “By increasing the Technology Readiness Level of our cell-free approach, we can pave the way for the conversion of renewable sugars into isobutanol at an industrial scale.”

Invizyne’s vision extends beyond just biofuels. Michael Heltzen, CEO of Invizyne, emphasizes the broader applicability of their technology. “While this project focuses on SAF, it establishes a framework for applying our cell-free platform to various industrial processes,” he stated. “With our recent IPO, we are well-positioned to become a leader in next-generation biomanufacturing, fostering a shift towards renewable solutions and a significant reduction in greenhouse gas emissions.”

About Invizyne Technologies

Invizyne Technologies is a California-based company pioneering cell-free, enzyme-based biomanufacturing. Their innovative SimplePath™ platform leverages natural enzymes to efficiently transform renewable resources into valuable biochemicals. Invizyne believes their technology offers a more sustainable and cost-effective alternative to traditional methods, with applications in pharmaceuticals, fuels, flavors, and more.

About BioMADE

BioMADE is a public-private partnership supported by the U.S. Department of Defense, working to strengthen American competitiveness in bioindustrial manufacturing. Through collaboration with a network of nearly 300 members, BioMADE facilitates the development and commercialization of biomanufactured products, fostering job creation and a more sustainable future.